{"nctId":"NCT01854775","briefTitle":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","startDateStruct":{"date":"2013-05-06","type":"ACTUAL"},"conditions":["Acquired Immune Deficiency Syndrome (AIDS)","HIV Infections"],"count":129,"armGroups":[{"label":"Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF"]},{"label":"Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF"]},{"label":"Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF","Drug: E/C/F/TAF (Low Dose)"]}],"interventions":[{"name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"name":"E/C/F/TAF (Low Dose)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Cohort 1\n\n  * 12 years to \\< 18 years of age at baseline\n  * Weight greater than or equal to 35 kg (77 lbs)\n  * Plasma HIV-1 ribonucleic acid (RNA) levels of ≥ 1,000 copies/mL at screening (Roche COBAS TaqMan v2.0)\n  * Screening genotype report shows sensitivity to EVG, FTC and tenofovir (TFV)\n  * No prior use of any approved or experimental anti-HIV-1 drug for any length of time\n* Cohort 2\n\n  * 6 years to \\< 12 years of age at baseline\n  * Weight greater than or equal to 25 kg (55 lbs)\n  * Plasma HIV-1 RNA of \\< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is \\> 50 copies/mL) for ≥ 180 consecutive days (6 months) prior to screening on a stable antiretroviral regimen, without documented history of resistance to any component of E/C/F/TAF STR.\n* Cohort 3\n\n  * Age at baseline: ≥ 2 years old\n  * Weight at screening: ≥ 14 kg (31 lbs) to \\< 25 kg (55 lbs)\n  * Plasma HIV-1 RNA: \\< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is \\> 50 copies/mL) for ≥ 180 consecutive days (6 months) prior to screening on a stable antiretroviral regimen, without prior history of resistance to any component of E/C/F/TAF STR\n\nKey Exclusion Criteria:\n\n* Hepatitis B or hepatitis C virus infection\n* Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit.\n* Individuals experiencing decompensated cirrhosis\n* Pregnant or lactating females\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23840.1","spread":"6076.15"}]}]}]},{"type":"PRIMARY","title":"PK Parameter: AUCtau of EVG (Cohort 2)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33813.9","spread":"19536.30"}]}]}]},{"type":"PRIMARY","title":"PK Parameter: AUCtau of EVG (Cohort 3)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29666.6","spread":"17321.81"}]}]}]},{"type":"PRIMARY","title":"PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)","description":"AUClast is defined as the concentration of drug from time zero to the last observable concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188.9","spread":"105.45"}]}]}]},{"type":"PRIMARY","title":"PK Parameter: AUClast of TAF (Cohort 2)","description":"AUClast is defined as the concentration of drug from time zero to the last observable concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332.9","spread":"149.12"}]}]}]},{"type":"PRIMARY","title":"PK Parameter: AUCtau of TAF (Cohort 3)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"366.4","spread":"144.91"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)","description":"Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:\n\n* Fatal\n* Life-threatening\n* Disabling/incapacitating\n* Results in hospitalization or prolongs a hospital stay\n* A congenital abnormality\n* Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs","description":"TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:\n\n* Fatal\n* Life-threatening\n* Disabling/incapacitating\n* Results in hospitalization or prolongs a hospital stay\n* A congenital abnormality\n* Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs","description":"TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:\n\n* Fatal\n* Life-threatening\n* Disabling/incapacitating\n* Results in hospitalization or prolongs a hospital stay\n* A congenital abnormality\n* Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 1)","description":"Ctau is defined as the observed drug concentration at the end of the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300.8","spread":"243.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.4","spread":"39.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"44.97"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 2)","description":"Ctau is defined as the observed drug concentration at the end of the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370.0","spread":"438.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114.9","spread":"27.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"3.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":"162.01"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)","description":"Ctau is defined as the observed drug concentration at the end of the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277.5","spread":"223.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":"26.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":"23.02"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)","description":"Cmax is defined as the maximum concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2229.6","spread":"427.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166.8","spread":"107.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2265.0","spread":"510.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"4.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1202.4","spread":"421.21"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)","description":"Cmax is defined as the maximum concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3055.2","spread":"1180.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"313.3","spread":"191.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3397.4","spread":"916.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"5.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2079.4","spread":"970.81"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)","description":"Cmax is defined as the maximum concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3297.2","spread":"1720.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"286.6","spread":"206.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3007.4","spread":"1138.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"4.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1525.5","spread":"788.12"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: CL of EVG and TAF (Cohort 1)","description":"Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":"52.64"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: CL of EVG and TAF (Cohort 2)","description":"Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"5.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":"11.21"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: CL of EVG and TAF (Cohort 3)","description":"Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"6.27"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Vz of EVG and TAF (Cohort 1)","description":"Vz is defined as the volume of distribution of the drug after intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":"18.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":"32.54"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Vz of EVG and TAF (Cohort 2)","description":"Vz is defined as the volume of distribution of the drug after intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":"36.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"25.74"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: Vz of EVG and TAF (Cohort 3)","description":"Vz is defined as the volume of distribution of the drug after intravenous administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.5","spread":"28.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"11.07"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14424.4","spread":"3452.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"287.6","spread":"54.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8240.8","spread":"2972.94"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20629.2","spread":"3906.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"440.2","spread":"92.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15890.7","spread":"8208.78"}]}]}]},{"type":"SECONDARY","title":"PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)","description":"AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19468.1","spread":"5635.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"334.9","spread":"76.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14485.2","spread":"7166.10"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 24 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"0.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.25","spread":"0.645"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"0.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.26","spread":"0.712"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in CD4+ Cell Count at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"471","spread":"212.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":"175.2"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"471","spread":"212.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":"170.3"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"961","spread":"275.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-118","spread":"194.1"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"961","spread":"275.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66","spread":"203.6"}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1153","spread":"459.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-137","spread":"278.3"}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1153","spread":"459.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-179","spread":"319.2"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":"8.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"4.77"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":"8.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"5.19"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"6.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"3.97"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"6.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"4.37"}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":"6.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"4.40"}]}]}]},{"type":"SECONDARY","title":"Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":"6.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"3.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":50},"commonTop":["Upper respiratory tract infection","Respiratory tract infection","Vomiting","Diarrhoea","Abdominal pain"]}}}